Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone in Generalized Anxiety Disorder
NCT01629966Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Jun 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vilazodone in generalized anxiety disorder (GAD), sponsored by Forest Laboratories. Started Jun 2012; status: completed.
02
Drugs
vilazodone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT01629966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01629966.